Cagrilintide
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.
Novo Nordisk · Phase 1 · Completed · Enrollment 178
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Part A: NNC0174-1213 (SD1-SD5) | n/r | n/r | n/r | n/r | n/r |
| Part A: Cagrilintide (SDA and SDB) | n/r | n/r | n/r | n/r | n/r |
| Part A: Placebo | n/r | n/r | n/r | n/r | n/r |
| Part B: NNC0174-1213 (MD1-MD5) | n/r | n/r | n/r | n/r | n/r |
| Part B: Cagrilintide (MDA) | n/r | n/r | n/r | n/r | n/r |
| Part B: Placebo | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.